José Antonio Robles-Cervantes, Esperanza Martínez-Abundis, Manuel González-Ortiz, Lázaro Cárdenas-Camarena, Eduardo Hernández-Salazar, Rafael Olvera-Ozuna
Journal: Obesity surgery 2008;17(9):1242-7
PMID: 18074501
BACKGROUND
Metabolic syndrome is a group of pathological processes which involve insulin resistance, a biochemical and molecular disorder. Obesity appears to be the most frequent clinical component in metabolic syndrome. Subcutaneous fat, independent from visceral fat, is still controversial as a marker of the pathophysiology of insulin resistance.
METHODS
An open parallel-group clinical trial was performed of 12 women (age 30-40 years), with BMI from 30-33 kg/m2 and fasting glucose < or =110 mg/dl. 6 women were included in the "liposuction plus diet" group, and 6 were included in the "diet-only" group. Metabolic profile, including insulin tolerance test (ITT), leptin and tumor necrosis factor alpha (TNFalpha), was performed at baseline, 1 and 6 months in both groups. Subcutaneous and visceral fat was quantified with spiral tomography at baseline and after 6 months. Friedman and Wilcoxon test were used for intra-group differences, Mann-Whitney U for differences between groups, and Spearman test for correlation, with significance set at P<0.05.
RESULTS
No difference existed between groups regarding clinical characteristics and metabolic profile. In the liposuction group, the increase in insulin sensitivity was (3.8+/-0.86, 3.1+/-0.85, 4.5+/-1.02 %/min, P=0.08. Insulin sensitivity did not correlate with subcutaneous fat, leptin, or TNFalpha. Leptin diminished at 1 month (52.7+/-6.04 vs 31.6+/-11.9), P=0.028, and correlated with the subcutaneous fat (r=0.957). In the diet-only group, TNFalpha diminished at 6 months, P=0.046.
CONCLUSION
Subcutaneous abdominal fat correlates with leptin; nevertheless, it is a weak marker for TNFalpha and insulin sensitivity.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.